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MicrohemorrhageMicrobleeds are small lesions, appearing as black dots on T2*-weighted magnetic resonance imaging. They occur
frequently in Alzheimer's disease (AD), but the clinical relevance of these radiological observations remains
unclear. In this paper an overview is given on currently available evidence on the clinical relevance of microbleeds
in AD. The evidence linking microbleeds to severity of cognitive impairment in AD is not unambiguous. From the
existing literature, it seems reasonable to conclude that multiple microbleeds negatively impact cognitive
performance, but there is less consensus on the importance of location of microbleeds in this respect. Regarding
progression of disease, there is hardly any evidence thatmicrobleeds affect disease course in terms of progression
to AD in patients with MCI or with respect to rate of cognitive decline in AD patients. This may imply that
microbleeds simply do not affect disease course, but an alternative explanation for the negative ﬁndings
would be that these studies are hampered by selective drop-out, as individuals with many microbleeds have
an increased risk of (stroke-related) mortality.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Microbleeds are small lesions, appearing as black dots on T2*-
weighted magnetic resonance imaging. Microbleeds, which have long
been considered to be innocent observations on MRI, have now been
shown to occur more frequently in patients with Alzheimer's disease
(AD) than in the general population, with an estimated prevalence of
23% [1–5]. An example of microbleeds in a patient with AD is shown
in Fig. 1. Together with white matter hyperintensities and lacunes,
microbleeds can be considered a third expression of small vessel disease
on MRI. Many questions still surround the observation of microbleeds:
for example, it is unclear what their underlying pathological substrate
is. Furthermore, the clinical implications of microbleeds are insufﬁciently
known.
Based on mainly epidemiological evidence, the hypothesis has
been coined that the etiology of microbleeds differs according to
their location. Microbleeds with a deep location supposedly result
from underlying hypertensive vasculopathy, while microbleeds in a
lobar location are thought to reﬂect underlying cerebral amyloid
angiopathy (CAA). This makes microbleeds especially relevant in the
context of AD, in which diseases both amyloid pathology (including
amyloid deposition in parenchyma [plaques] and in vessels [CAA])
and ischemic vascular pathology play a role. It is not known how
these two types of pathology interact, but the fact that microbleedsal Center, de Boelelaan 1118,
40816; fax: +31 20 4440715.
lsevier OA license.appear to be related to both types of pathology makes them highly
relevant [5].
2. Microbleeds reﬂect amyloid burden
In a proof of principle study, we retrospectively selected AD patients
with many microbleeds (arbitrarily deﬁned as >8, corresponding to the
top 5%) and matched these for age and gender on a one-to-two basis
with AD patients without any microbleeds [6]. There were no differences
between groups in the degree of (medial temporal) atrophy. Patients
with many microbleeds however, had more severe white matter
hyperintensities, conﬁrming the association with small vessel disease.
Moreover, they had lower (i.e. more abnormal) levels of amyloid-beta
1–42 in their cerebrospinal ﬂuid (CSF), providing evidence for a link
with amyloid burden. We recently conﬁrmed the latter ﬁnding in a
completely independent sample of patients with ≥1 microbleed which
we comparedwith an age and gendermatched group of patients without
any microbleeds [7]. Patients with microbleeds had lower (i.e. more
abnormal) levels of CSF amyloid-beta 1–42, but contrary to our expec-
tation, there was no relation with CSF amyloid-beta 1–40. This may
have several potential explanations. First, microbleeds in AD may repre-
sent an earlier stage or milder form of CAA compared to sporadic CAA
patients presenting with full blown hemorrhages. Alternatively, AD
patients may have a different subtype of CAA, arising from a different
pathomechanism. The ﬁnding of lowered amyloid-beta 1–42 was
largely attributable to patients with lobar microbleeds, providing
circumstantial evidence that lobar microbleeds in AD are related to
CAA. Additional evidence for a spatial relationship between microbleeds
and amyloid-beta comes from an elegant study using Positron Emission
Fig. 1. A 56-year old female patient with Alzheimer's disease. On the Mini-Mental State Examination, she has a score of 16. On MRI, axial susceptibility-weighted imaging (left
panel) shows multiple lobar microbleeds. On the coronal T1-weighted image (right panel), atrophy of the medial temporal lobe can be appreciated.
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local increase in PIB retention at the site of microbleeds [8]. Regions of
interest in concentric circles around the microbleed showed a gradual
decline in PIB retention with increasing distance from the microbleed
location.
3. ARIA
The studies above underline the relevance of microbleeds in the
context of AD. Interest in microbleeds has further boosted because
of the observation of microbleeds and vasogenic edema as side effects
of immunization therapy [9,10]. This has led to the recent introduction of
the term Amyloid Related Imaging Abnormalities (ARIA) [11]. ARIA en-
compass both vasogenic edema related observations (ARIA-E) suppos-
edly reﬂecting an increase in extracellular ﬂuid, and hemosiderin-
related observations (ARIA-H). The latter include both microbleeds and
superﬁcial siderosis. The article attempts to provide recommendations
for the detection and monitoring of ARIA in AD clinical trials, but at the
same time acknowledges that many aspects regarding the etiology of
these radiological observations, and especially regarding their clinical
relevance remain unclear. In the remainder of this paper, I will give an
overview of currently available evidence on the clinical relevance of
microbleeds in AD. First, I will focus on cross-sectional studies studying
the relationship between microbleeds and severity of cognitive impair-
ment. Subsequently, I will discuss the relationship between microbleeds
and rate of decline.
4. Cognitive impairment
Most studies in AD have shown hardly any relationship between the
presence of microbleeds and cognition [1,2,4,12]. The relatively small
sample sizes and the low number of microbleeds (most patients with
microbleeds have only onemicrobleed) may account for these negative
ﬁndings. Alternatively, the disease process may have advanced too far,
masking the subtle effect of microbleeds on cognition. To account for
the problem of low number ofmicrobleeds, we took a proof of principle
approach, comparing AD patients with many microbleeds to age and
gender matched AD patients without any microbleeds [6]. We found
that patients with many microbleeds performed ﬁve points worse on
their Mini-Mental State Examination at ﬁrst examination. This effect
remained signiﬁcant after adjustment for age, gender, medial temporal
lobe atrophy and white matter hyperintensities, and shows that
number of microbleeds may be a highly relevant factor to take into
account.
Epidemiological studies of large cohorts of non-demented individuals
may reveal the subtle impact of microbleeds on cognition that maybecome obscured later in the disease process. In the Rotterdam study, a
respectable number of 3979 elderly from the general population (60±
9 years; 54% female, MMSE 28±2, ≥1 microbleed: 15%) were included
[13]. The researchers found an association between a higher number of
microbleeds and lower MMSE-score and worse performance on tests
for information processing speed and motor speed. These associations
were mostly attributable to individuals with many microbleeds (≥5),
preferably with a lobar location. In a non-demented cohort of 500
patients with small vessel disease (RUN DMC cohort; 66±9 years;
43% female, MMSE 28±2, ≥1 microbleed: 10%) associations between
both presence and number of microbleeds and measures of global
cognition, memory, speed and attention were found [14]. The relation-
ship betweenmicrobleeds and cognitive performance wasmainly driven
by frontal and temporal (lobar) microbleeds. Additionally, deep micro-
bleeds were related to worse global cognitive function, psychomotor
speed and attention. Finally, the PROSPER study investigated 439
nondemented individualswith vascular risk factors (78±3 years; 40% fe-
male, MMSE 28,≥1microbleed: 24%) and found no effect of microbleeds
on cognitive performance [15]. In a direct comparison between patients
with infratentorial microbleeds and patients without infratentorial
microbleeds (including patients with microbleeds in another location)
however, they found that the former group performedworse onmemory
tests.
5. Rate of decline
Subsequently, onemay questionwhether the presence ofmicrobleeds
negatively impacts the course of the disease. Progression of disease can be
deﬁned in a number of ways. A ﬁrst and important question is whether
the presence of microbleeds predicts progression to AD among patients
with mild cognitive impairment (MCI). We followed 152 patients with
MCI presenting at our memory clinic for an average of 2±1 years [16].
At follow-up, 80 patients (53%) had remained stable, 56 (37%) had
developed AD, and 16 (10%) had developed another type of dementia
(e.g. vascular dementia, frontotemporal dementia, dementia with
Lewy bodies). On baseline MRI, atrophies of the medial temporal lobe
and white matter hyperintensities were graded using a simple visual
rating scale and microbleeds were counted. We found that atrophy of
the medial temporal lobe predicted progression to AD, while white
matter hyperintensities and presence of microbleeds predicted progres-
sion to another type of dementia, but not to AD.
A second way to look at progression of disease, is by looking at rate
of cognitive decline. We followed 221 patients with AD (68±9 years;
49% female, baselineMMSE 22±4,≥1microbleed: 18%) for an average
duration of follow-up of 3±1 years [17]. Cognitive performance was
repeatedly measured using MMSE. Linear mixed models showed that
58 W.M. van der Flier / Journal of the Neurological Sciences 322 (2012) 56–58on average, patients lost 2MMSE points per year. There was no relation
between presence or number of microbleeds and baseline MMSE or
change in MMSE over time. Results did not change when we took loca-
tion of microbleeds into account. It is still possible that subtle effects of
microbleeds on rate of decline in speciﬁc cognitive domainswould have
been found when other neuropsychological tests had been used. None-
theless, the abovementioned study shows that presence and number of
microbleeds are not a major determinant of disease course.
A third way to look at disease progression is by taking mortality
as outcomemeasure. We followed 1138 patients from ourmemory clinic
(including 357 patients with AD) for an average period of 3±2 years
[18]. Information on mortality was obtained from the general
practicioner and/or the patient ﬁle. Baseline MRI was assessed using
simple visual rating scales for atrophy of themedial temporal lobe, global
cortical atrophy, white matter hyperintensities and microbleeds (catego-
rized as 0/1–2/≥3). We found that the presence of multiple microbleeds
was the strongest predictor of mortality with an almost two and a half
times increased risk of mortality, after adjustment for other MRI-
measures and vascular risk factors. In this study, information on cause
of death was not available. An attempt to take into account the cause of
deathwasmade in a study based on the PROPSER cohort [19]. The cohort
of 435 nondemented individuals with vascular risk factors was followed
for 7±2 years. Information on cause of death was obtained from the
Central Bureau of Statistics of the Netherlands. In this study, multiple
(>1) microbleeds modestly though non-signiﬁcantly, predicted overall
mortality, but they strongly predicted stroke-related mortality (hazard
ratio 6). Furthermore, this increased risk of stroke-related mortality
was largely attributable to microbleeds with a strictly lobar distribution.
6. Conclusion and discussion
Microbleeds are a radiological construct, reﬂecting deposits of
hemosiderin. They can presumably result from two neuropathological
routes; [1] hypertensive vasculopathy and [2] cerebral amyloid
angiopathy. Microbleeds are of particular interest in the context of AD
for a number of reasons. First, their prevalence is higher in patients
with AD than in the general population. Second, resulting from two
neuropathological routes, they may form a bridge between amyloid
initiated brain changes and ischemic cerebrovascular pathology. Associ-
ations with expressions of small vessel disease on the one hand and
with amyloid-beta on the other hand provide evidence for this double
association. Finally, interest in microbleeds has boosted due to
their occurrence as side effect of anti-amyloid immunization therapy
[11]. At the same time, relatively little is known about their clinical
relevance.
The evidence linking microbleeds to severity of cognitive impairment
is not unambiguous. From the existing literature, we can conclude that
multiple microbleeds negatively impact cognitive performance. There
is no consensus on the importance of location of microbleeds in this
respect, however. The conﬂicting ﬁndings may be partly explained by
the speciﬁc characteristics of the cohorts under study. In the context of
(preclinical) AD, lobar microbleeds may impact cognitive performance
most, while in the context of cerebrovascular disease, microbleeds with
a deep or infratentorial location may have a stronger impact on cognitive
performance.
Regarding progression of disease, it seems that microbleeds do not
affect the course of AD in terms of progression to AD in patients with
MCI or with respect to rate of cognitive decline. A potential explanation
for this ﬁnding is that microbleeds have only a subtle effect on cognition
and disease course, which is diluted once the disease has progressed too
far. An alternative explanation would be that selective drop-out accounts
for the negative ﬁndings in longitudinal studies. This would be the
case when patients with multiple microbleeds are at risk of such
fast disease progression that they are less likely to return to the memory
clinic for follow-up evaluation. Circumstantial evidence for this line of
reasoning stems from studies showing that individuals with manymicrobleeds have an increased risk of (stroke-related) mortality [18,19].
In the context of clinical trials, this means that one or a few microbleeds
seem to be unharmful, but patients with many microbleeds should not
be exposed to unnecessary risks [11]. At this point, there is insufﬁcient ev-
idence to make recommendations about the speciﬁc number of
microbleeds that might be harmful. Moreover, it is not known yet if
microbleeds developing as a result of immunization trials (i.e. ARIA-H)
have the same neuropathological substrate and risk proﬁle as spontane-
ously developingmicrobleeds. This implies that we do not know yet if re-
sults of studies on risks associatedwithmicrobleeds can be generalized to
ARIA-H. Furthermore, data regarding the question whether baseline
microbleeds actually increase the risk of incident hemorrhage and
vasogenic edema (ARIA-E) are dearly needed.Conﬂict of interest
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